https://www.live-feeds.com/feed/summit-packs-a-punch-for-merck-s-keytrudaContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/summit-packs-a-punch-for-merck-s-keytrudahttps://www.live-feeds.com/feed/summit-packs-a-punch-for-merck-s-keytruda#u57725Sat, 05 Sep 2026 03:55:51 +0000Summit Therapeutics and Akeso report that ivonescimab extended lives more effectively than Merck's Keytruda in a Phase 3 head-to-head trial conducted in China. The drug cleared the overall survival bar, positioning it as a direct competitor to the established immunotherapy. While Summit claims the drug is beating Merck, some analysts remain skeptical of the results. This development marks a second time ivonescimab has bested Keytruda in trials within China, challenging the market dominance of Merck's flagship cancer treatment.Why it mattersKeytruda is a primary standard of care for l